These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1079 related items for PubMed ID: 9360783

  • 21. Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma.
    Blayney DW, McGuire BW, Cruickshank SE, Johnson DH.
    Oncologist; 2005 Feb; 10(2):138-49. PubMed ID: 15709216
    [Abstract] [Full Text] [Related]

  • 22. Efficacy of an early intensification treatment integrating chemotherapy, autologous stem cell transplantation and radiotherapy for poor risk primary mediastinal large B cell lymphoma with sclerosis.
    Cairoli R, Grillo G, Tedeschi A, Gargantini L, Marenco P, Tresoldi E, Barbarano L, Nosari AM, Morra E.
    Bone Marrow Transplant; 2002 Mar; 29(6):473-7. PubMed ID: 11960265
    [Abstract] [Full Text] [Related]

  • 23. A novel high-dose chemotherapy protocol with autologous hematopoietic rescue in patients with metastatic breast cancer or recurrent non-Hodgkin's lymphoma.
    Fontelonga A, Kelly AJ, MacKintosh FR, Hall S, Monroe P, Wilson GS, Shaft D, Ruthven A, Ascensao JL.
    Bone Marrow Transplant; 1997 May; 19(10):983-8. PubMed ID: 9169642
    [Abstract] [Full Text] [Related]

  • 24. Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival.
    van Besien K, Rodriguez A, Tomany S, Younes A, Donato M, Sarris A, Giralt S, Mehra R, Andersson B, Gajewski J, Champlin R, Cabanillas F.
    Bone Marrow Transplant; 2001 Feb; 27(4):397-404. PubMed ID: 11313669
    [Abstract] [Full Text] [Related]

  • 25. [Preliminary outcome for patients with relapsed or resistant advanced non-Hodgkin's lymphoma treated by EPOCH regimen].
    Huang HQ, Jiang WQ, Wang W, Zhou ZM, Xia ZJ, Lin XB, Li YH, Xu RH, Zhang L, Xu GC, Sun XF, Liu DG, He YJ, Guan ZZ.
    Ai Zheng; 2003 Apr; 22(4):389-92. PubMed ID: 12703995
    [Abstract] [Full Text] [Related]

  • 26. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Stamatoullas A, Fruchart C, Bastit D, Boulet D, Moncondult M, Piguet H, Tilly H.
    Cancer; 1996 Jun 01; 77(11):2302-7. PubMed ID: 8635099
    [Abstract] [Full Text] [Related]

  • 27. Phase I study of involved-field radiotherapy preceding autologous stem cell transplantation for patients with high-risk lymphoma or Hodgkin's disease.
    Dawson LA, Saito NG, Ratanatharathorn V, Uberti JP, Adams PT, Ayash LJ, Reynolds CM, Silver SM, Schipper MJ, Lichter AS, Eisbruch A.
    Int J Radiat Oncol Biol Phys; 2004 May 01; 59(1):208-18. PubMed ID: 15093918
    [Abstract] [Full Text] [Related]

  • 28. High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma.
    Weaver CH, Schwartzberg L, Rhinehart S, West J, Zhen B, West WH, Buckner CD.
    Bone Marrow Transplant; 1998 Feb 01; 21(4):383-9. PubMed ID: 9509973
    [Abstract] [Full Text] [Related]

  • 29. High-dose sequential chemotherapy with autologous blood stem cell rescue for relapsed or resistant lymphoma.
    Sanna P, Van den Bosch S, Cavalli F, Ghielmini M.
    Schweiz Med Wochenschr; 1998 Oct 03; 128(40):1500-7. PubMed ID: 9888164
    [Abstract] [Full Text] [Related]

  • 30. [A multicenter early phase II study of high-dose chemotherapy with autologous peripheral blood stem cell transplantation for treatment of intermediate-grade non-Hodgkin's lymphoma. Japan Blood Cell Transplantation Study Group].
    Chou T, Ishiguro T, Imajo K, Kawano F, Gondo H, Kasai M, Masuda M, Koike M, Shimazaki C, Hara M, Shinagawa K, Ogawa M, Takaku F, Harada M.
    Rinsho Ketsueki; 1999 Oct 03; 40(10):1058-67. PubMed ID: 10565222
    [Abstract] [Full Text] [Related]

  • 31. High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality.
    Wadhwa PD, Fu P, Koc ON, Cooper BW, Fox RM, Creger RJ, Bajor DL, Bedi T, Laughlin MJ, Payne J, Gerson SL, Lazarus HM.
    Biol Blood Marrow Transplant; 2005 Jan 03; 11(1):13-22. PubMed ID: 15625540
    [Abstract] [Full Text] [Related]

  • 32. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity.
    Jo JC, Kang BW, Jang G, Sym SJ, Lee SS, Koo JE, Kim JW, Kim S, Huh J, Suh C.
    Ann Hematol; 2008 Jan 03; 87(1):43-8. PubMed ID: 17710401
    [Abstract] [Full Text] [Related]

  • 33. Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma.
    Schmitz N, Kloess M, Reiser M, Berdel WE, Metzner B, Dorken B, Kneba M, Trumper L, Loeffler M, Pfreundschuh M, Glass B, German High-Grade Non Hodgkin's Lymphoma Study Group (DSHNHL).
    Cancer; 2006 Jan 01; 106(1):136-45. PubMed ID: 16331635
    [Abstract] [Full Text] [Related]

  • 34. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
    Kanteti R, Miller K, McCann J, Roitman D, Morelli J, Hurley C, Berkman E, Schenkein D.
    Bone Marrow Transplant; 1999 Sep 01; 24(5):473-81. PubMed ID: 10482930
    [Abstract] [Full Text] [Related]

  • 35. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
    Klumpp TR, Mangan KF, Glenn LD, Malaspina DR, Cropper T, Mullaney M, Macdonald JS.
    Bone Marrow Transplant; 1993 Oct 01; 12(4):337-45. PubMed ID: 7506091
    [Abstract] [Full Text] [Related]

  • 36. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
    Hainsworth JD, Wolff SN, Stein RS, Greer JP, Cousar JB, Greco FA.
    Cancer Treat Rep; 1986 Aug 01; 70(8):953-8. PubMed ID: 3015406
    [Abstract] [Full Text] [Related]

  • 37. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support.
    Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C, Gressin R, Lucas V, Colombat P, Harousseau JL, Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang.
    N Engl J Med; 2004 Mar 25; 350(13):1287-95. PubMed ID: 15044639
    [Abstract] [Full Text] [Related]

  • 38. Cyclophosphamide, etoposide and carboplatine plus non-cryopreserved autologous peripheral blood stem cell transplantation rescue for patients with refractory or relapsed non-Hodgkin's lymphomas.
    Mabed M, Al-Kgodary T.
    Bone Marrow Transplant; 2006 Apr 25; 37(8):739-43. PubMed ID: 16501587
    [Abstract] [Full Text] [Related]

  • 39. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
    Sieber M, Bredenfeld H, Josting A, Reineke T, Rueffer U, Koch T, Naumann R, Boissevain F, Koch P, Worst P, Soekler M, Eich H, Müller-Hermelink HK, Franklin J, Paulus U, Wolf J, Engert A, Diehl V, German Hodgkin's Lymphoma Study Group.
    J Clin Oncol; 2003 May 01; 21(9):1734-9. PubMed ID: 12721249
    [Abstract] [Full Text] [Related]

  • 40. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.
    Damon L, Rugo H, Tolaney S, Navarro W, Martin T, Ries C, Case D, Ault K, Linker C.
    Biol Blood Marrow Transplant; 2006 Mar 01; 12(3):316-24. PubMed ID: 16503501
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 54.